mash tirzepatide hits two receptors. Semaglutide hits one. The liver feels the difference. Both drugs work in MASH. The question is whether the second receptor — GIP — adds meaningful hepatic benefit beyond EBM BLS: Tirzepatide Leads to

A clinical second look means examining the skin directly, and then asking a second question most pathways skip: what internal evidence would explain a pattern like this metabolic, hormonal, inflammatory

A.MalikR

Researchers are now exploring GLP-1 drugs as potential treatments for substance-use disorders

That doesnt necessarily mean everyone should pursue it

PubMed Central , Clinical and Experimental Pharmacology & Physiology , vol

If NAION is confirmed, treatment with semaglutide should be stopped. In January, the agency said it would start looking into the issue after somebut not allstudies indicated that there was an association between semaglutide treatment and NAION